Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized, Active-Controlled Dose Titration Study to Assess the Efficacy and Safety of SHR6508 in Hemodialysis Subjects With Secondary Hyperparathyroidism

NCT05663411 is registered in ClinicalTrials.gov with Shanghai Hengrui Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05663411
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05663411 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized, Active-Controlled Dose Titration Study to Assess the Efficacy and Safety of SHR6508 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Lead sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
February 24, 2023
Completion date
November 30, 2023
Enrollment
75 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

secondary hyperparathyroidism